Free Trial
NYSEAMERICAN:ARMP

Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis

Armata Pharmaceuticals logo
$2.60 0.00 (0.00%)
Closing price 04:10 PM Eastern
Extended Trading
$2.60 0.00 (0.00%)
As of 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP)

Key Stats

Today's Range
$2.56
$2.65
50-Day Range
$1.84
$2.71
52-Week Range
$0.90
$2.96
Volume
6,968 shs
Average Volume
103,519 shs
Market Capitalization
$94.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

Armata Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

ARMP MarketRank™: 

Armata Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Armata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Armata Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Armata Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Armata Pharmaceuticals are expected to decrease in the coming year, from ($0.95) to ($1.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Armata Pharmaceuticals is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Armata Pharmaceuticals is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Armata Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.47% of the float of Armata Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Armata Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Armata Pharmaceuticals has recently decreased by 24.85%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Armata Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Armata Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.47% of the float of Armata Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Armata Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Armata Pharmaceuticals has recently decreased by 24.85%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      84.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 3.57% of the stock of Armata Pharmaceuticals is held by institutions.

    • Read more about Armata Pharmaceuticals' insider trading history.
    Receive ARMP Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    ARMP Stock News Headlines

    Armata Pharmaceuticals Q3 EPS Boosted by HC Wainwright
    A New Way to Double Your Retirement Income?
    Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
    Armata Pharmaceuticals Inc.
    See More Headlines

    ARMP Stock Analysis - Frequently Asked Questions

    Armata Pharmaceuticals' stock was trading at $2.00 at the start of the year. Since then, ARMP stock has increased by 31.0% and is now trading at $2.62.

    Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) released its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.02. The company had revenue of $1.23 million for the quarter, compared to analyst estimates of $0.90 million.

    Armata Pharmaceuticals' top institutional shareholders include GSB Wealth Management LLC (0.08%).
    View institutional ownership trends
    .

    Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Altimmune (ALT), Vaxart (VXRT), Pfizer (PFE), Advanced Micro Devices (AMD), Co-Diagnostics (CODX) and Amarin (AMRN).

    Company Calendar

    Last Earnings
    11/14/2023
    Today
    8/26/2025
    Next Earnings (Estimated)
    11/12/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NYSEAMERICAN
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NYSEAMERICAN:ARMP
    CIK
    921114
    Employees
    70
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $9.00
    Low Price Target
    $9.00
    Potential Upside/Downside
    +244.2%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($1.64)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$18.92 million
    Net Margins
    -374.30%
    Pretax Margin
    -374.30%
    Return on Equity
    N/A
    Return on Assets
    -24.00%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    0.06
    Quick Ratio
    0.06

    Sales & Book Value

    Annual Sales
    $5.17 million
    Price / Sales
    18.33
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    ($1.33) per share
    Price / Book
    -1.97

    Miscellaneous

    Outstanding Shares
    36,230,000
    Free Float
    5,616,000
    Market Cap
    $94.74 million
    Optionable
    Not Optionable
    Beta
    0.99
    10 Best Stocks to Own: Fall 2025 Cover

    Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

    Get This Free Report

    This page (NYSEAMERICAN:ARMP) was last updated on 8/26/2025 by MarketBeat.com Staff
    From Our Partners